Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy

Background: In the U.S., more than 50% of ovarian cancer patients die within 5 years of diagnosis, highlighting the need for innovations such as engineered T cell therapies. Mesothelin (Msln) is an attractive immunotherapy target for this cancer, as it is overexpressed by the tumor and contributes t...

Full description

Saved in:

Bibliographic Details
Published in:	bioRxiv
Main Authors:	Anderson, Kristin G, Oda, Shannon K, Bates, Breanna M, Burnett, Madison G, Magdalia Rodgers Suarez, Ruskin, Susan L, Greenberg, Philip D
Format:	Paper
Language:	English
Published:	Cold Spring Harbor Cold Spring Harbor Laboratory Press 31.07.2021 Cold Spring Harbor Laboratory
Edition:	1.1
Subjects:	Adoptive immunotherapy Antitumor agents Apoptosis Cell activation Cell death Cell proliferation Cell survival Cell therapy Cytokines FasL protein Fusion protein Immunology Immunomodulation Immunotherapy Invasiveness Lymphocytes Lymphocytes T Ovarian cancer Phenotypes Solid tumors T cell receptors Tumor cells Tumor microenvironment Tumor-infiltrating lymphocytes Tumors Adoptive T cell Immunotherapy Immuno-modulatory Fusion Protein High Grade Serous Ovarian Cancer Immunocompetent Mouse Model
ISSN:	2692-8205, 2692-8205
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!